2024-25 Cost Recovery Implementation Statement (CRIS) for the administration of the Prescribed List of Medical Devices and Human Tissue Products (PL)
The 2024-25 CRIS for the administration of the PL has been updated to include:
- financial results for 2023-24
- financial forecasts for 2024-25 and future financial years
- arrangements for the 2024-25 levy.
2024-25 Prescribed List cost recovery levy
There has been a change to the 2024-25 Prescribed List levy with the levy amount set at $150, which is lower than the indicative range of $350-$450 provided in the draft 2024-25 CRIS. This is due to the exclusion of compliance and post-listing review costs from the 2024-2025 levy, as these costs are already funded by the 2021-22 Budget measure to modernise and improve the administration of the Prescribed List.
The levy date for 2024-25 is 15 March 2025. Sponsors of medical devices listed on the Prescribed List will be invoiced via the Health Products Portal (HPP) on or shortly after this date, with the standard 28-day payment terms. The department will contact sponsors that are yet to register their details on the HPP.
Please be aware that the levy date is dependent on finalisation and registration of the required legislative instruments. Sponsors will be notified should there be any change to timing.
From 2025-26, the levy date will be on 15 September each year. The levy amount for 2025-26 and thereafter will include costs for compliance and post-listing reviews. The levy amount for the next financial year will be communicated through the draft 2025-26 CRIS in the coming months.